First molecular-based anti-TB drug resistance survey in Eritrea.

Autor:	Mesfin AB; Communicable Diseases Control Division, Asmara, Eritrea., Araia ZZ; Communicable Diseases Control Division, Asmara, Eritrea., Beyene HN; Communicable Diseases Control Division, Asmara, Eritrea., Mebrahtu AH; Communicable Diseases Control Division, Asmara, Eritrea., Suud NN; National Health Laboratory, Ministry of Health, Asmara, Eritrea., Berhane YM; National Health Laboratory, Ministry of Health, Asmara, Eritrea., Hailu DT; National Health Laboratory, Ministry of Health, Asmara, Eritrea., Kassahun AZ; Eritrea Country Office, World Health Organization, Asmara, Eritrea., Auguet OT; Global TB Programme, World Health Organization, Geneva, Switzerland., Dean AS; Global TB Programme, World Health Organization, Geneva, Switzerland., Cabibbe AM; Emerging Bacterial Pathogens Unit, Division of Immunology, Transplantation and Infectious Diseases, Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele Scientific Institute, Milan, Italy., Cirillo DM; Emerging Bacterial Pathogens Unit, Division of Immunology, Transplantation and Infectious Diseases, Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele Scientific Institute, Milan, Italy.
Jazyk:	angličtina
Zdroj:	The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease [Int J Tuberc Lung Dis] 2021 Jan 01; Vol. 25 (1), pp. 43-51.
DOI:	10.5588/ijtld.20.0558
Abstrakt:	BACKGROUND: In the absence of reliable data on drug-resistant TB in Eritrea, a national survey was conducted in 2018 using molecular-based methods, bypassing the need for culture. METHODS: A cross-sectional study was conducted in all 77 TB microscopy centres in the country. All 629 newly registered sputum smear-positive pulmonary TB patients were enrolled over 12 months. Sputum samples were tested using the Xpert ® MTB/RIF assay and targeted next-generation sequencing (Deeplex Myc-TB) to identify resistance and explore the phylogenetics of Mycobacterium tuberculosis complex strains. RESULTS: Drug resistance profiles were obtained for 555 patients (502 new, 53 previously treated). The prevalence of rifampicin-resistant TB (RR-TB) was respectively 2.0% and 7.6% among new and previously treated cases. All RR-TB isolates that were susceptible to isoniazid displayed a phylogenetic marker conferring capreomycin resistance, confirming circulation of a previously described resistant TB sub-lineage in the Horn of Africa. Only one case of fluoroquinolone resistance was detected. CONCLUSION: The prevalence of rifampicin resistance among TB patients is encouragingly low. The scarcity of fluoroquinolone resistance bodes well for the success of the recommended all-oral treatment regimen. Surveillance based on molecular approaches enables a reliable estimation of the burden of resistance and can be used to guide appropriate treatment and care.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu